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Abstract
Background
The Global Burden of Disease Study 2010 (GBD 2010), estimated that a substantial propor-
tion of the world’s disease burden came from mental, neurological and substance use disor-
ders. In this paper, we used GBD 2010 data to investigate time, year, region and age
specific trends in burden due to mental, neurological and substance use disorders.
Method
For each disorder, prevalence data were assembled from systematic literature reviews.
DisMod-MR, a Bayesian meta-regression tool, was used to model prevalence by country,
region, age, sex and year. Prevalence data were combined with disability weights derived
from survey data to estimate years lived with disability (YLDs). Years lost to premature mor-
tality (YLLs) were estimated by multiplying deaths occurring as a result of a given disorder
by the reference standard life expectancy at the age death occurred. Disability-adjusted life
years (DALYs) were computed as the sum of YLDs and YLLs.
Results
In 2010, mental, neurological and substance use disorders accounted for 10.4% of global
DALYs, 2.3% of global YLLs and, 28.5% of global YLDs, making them the leading cause of
YLDs. Mental disorders accounted for the largest proportion of DALYs (56.7%), followed by
neurological disorders (28.6%) and substance use disorders (14.7%). DALYs peaked in
early adulthood for mental and substance use disorders but were more consistent across
age for neurological disorders. Females accounted for more DALYs in all mental and
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neurological disorders, except for mental disorders occurring in childhood, schizophrenia,
substance use disorders, Parkinson’s disease and epilepsy where males accounted for
more DALYs. Overall DALYs were highest in Eastern Europe/Central Asia and lowest in
East Asia/the Pacific.
Conclusion
Mental, neurological and substance use disorders contribute to a significant proportion of
disease burden. Health systems can respond by implementing established, cost effective
interventions, or by supporting the research necessary to develop better prevention and
treatment options.
Introduction
A substantial proportion of the world’s health problems in both high-income countries (HICs)
and low-to-middle-income countries (LMICs) arises from mental, neurological, and substance
use disorders [1,2]. Treatment rates for these disorders are low, particularly in LMICs, where
treatment gaps of more than 90% have been documented. Even in HICs, where rates of treat-
ment are comparatively higher, treatment for mental, neurological, and substance use disorders
tends to be provided many years after the onset of the disorder [3,4].
Historically, major health policy decisions have been informed by mortality statistics. Al-
though our understanding of diseases causing premature mortality expanded as a result, the
lack of emphasis on morbidity undervalued the global impact of prevalent and disabling disor-
ders with lower mortality, such as mental, neurological, and substance use disorders. Until re-
cently, there was a poor understanding of the comparative global epidemiology of mental,
neurological, and substance use disorders and slower progress compared to other disorders in
identifying the most cost-effective interventions. Although these disorders exist in all countries,
cultures also influence their development and presentation. The predominantly Western-based
definitions of mental, neurological, and substance use disorders can be in conflict with cultural
contexts[5], leading to challenges in assembling data on global epidemiology. For example,
some languages do not have the words to describe concepts such as “sadness” or “depression”
as they are described in Western countries. Epidemiological surveys in many LMICs tend to
capture somatic manifestations of disorders such as depression and anxiety, which may not be
as relevant to other countries and cultures [6–8]. Furthermore, explanations for the onset and
progression of mental, neurological, and substance use disorders may be explained through
mechanisms such the presence of spirits or curses rather than as medical disorders [5].
To improve the health outcomes of people with mental, neurological, and substance use disor-
ders in both HICs and LMICs, it is important to understand not only the number and distribution
of these disorders among countries, but also how they impact on health in terms of both mortality
and disability, compared with other diseases and injuries. The first Global Burden of Disease
Study (GBD 1990), which published data on disease burden in 1990 [9], reported that the category
of mental, neurological, and substance use disorders—a grouping that included depression, select-
ed anxiety disorders, bipolar disorder, schizophrenia, epilepsy, dementia, Parkinson’s disease,
multiple sclerosis, alcohol, and drug use disorders—accounted for a significant proportion of the
world’s disease burden, as measured by disability-adjusted life years (DALYs). The DALY is
a health metric that captures the non-fatal component of the disease burden as years live with dis-
ability (YLDs), and the fatal component as years lost to premature mortality (YLLs) [9].
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Findings from the Global Burden of Disease Study 2010 (GBD 2010), the most recent bur-
den of disease study, were released in 2012. GBD 2010 was a comprehensive re-analysis of bur-
den for 291 diseases and injuries and 67 risk factors [1,10–14]. It included the complete
epidemiological reassessment of all diseases, injuries, and risk factors across 187 countries;
21 world regions; men and women; 1990, 2005, 2010; and 20 different age groups. Compared
to GBD 1990, in GBD 2010 an expanded list of mental, neurological and substance use disor-
ders were assessed. Rather than rely on a selective sample of data points, burden estimates were
based on a systematic review of the literature to obtain all available epidemiological data. They
were also derived using new statistical methods to model the epidemiological data, quantify
disability, adjust for comorbidity between diseases, and propagate uncertainty [1,11]. Overall,
GBD 2010 findings highlighted a shift in burden from communicable to noncommunicable
diseases and from YLLs to YLDs [1,11]. Although communicable diseases remain a health pri-
ority in many LMICs, increasing life expectancies due to better reproductive health, childhood
nutrition, and control of communicable diseases meant that more people in 2010 were living to
ages where mental, neurological, and substance use disorders were most prevalent [15].
In GBD 2010, the burden of mental and substance use disorders were estimated separately
from that of neurological disorders, such as dementia, Parkinson’s disease, and epilepsy. This
approach was done to better accommodate differences in the burden between these groups of
disorders. Mental and substance disorders were one of the leading causes of disease burden in
2010. They were responsible for 7.4% of global DALYs and 22.9% of global YLDs, making
them the fifth leading cause of DALYs and the leading cause of YLDs [15]. Neurological disor-
ders explained 3% of global DALYs and 5.6% of global YLDs [1,11]. The overarching findings
of the study for all 291 diseases and injuries have been presented [1,10–14], as have findings for
mental and substance use disorders [15,16]. This paper presents GBD 2010 burden estimates
of mental, neurological and substance use disorders as a group. Analysing burden estimates at
this aggregated level is important from both the clinical and population-health perspectives,
given that the organization of services in many LMICs does not separate neurological disorders
from mental disorders, something seen as a progression of Western medical subspecialization.
Specifically, in this paper, we quantify the global disease burden attributable to mental, neuro-
logical, and substance use disorders and explore variations in burden by disorder type, age,
gender, year, and region.
Methods
This section summarizes how YLDs, YLLs, and DALYs were estimated for mental, neurologi-
cal, and substance use disorders in GBD 2010. More detailed information about the input data
and methods can be accessed elsewhere [8,15–23].
Case Definition
Table 1 summarizes the mental, neurological, and substance use disorders in the GBD 2010
cause list. This included an extended list of disorders compared to previous GBD studies. To
allow for comparability in measurement, the definitions of dementia, mental, and substance
use disorders used for GBD 2010 were restricted to diagnostic classifications provided in the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [24] and the Internation-
al Classification of Diseases (ICD-10) [25]. The epilepsy definition was based on ICD-10 [25].
Estimation of Years Lived with Disability
Unlike GBD 1990, which estimated incident-YLDs, GBD 2010 estimated prevalent-YLDs
by multiplying the prevalence of a given condition by its disability weight, and without
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age-weighting and discounting, both of which had been used in earlier GBD studies[26]. As
these, in combination with other factors, such as newly derived disability weights, changed the
DALY metric from GBD 1990, the YLDs in GBD 2010 were recalculated for 1990, as well as for
2005 and 2010, to facilitate the investigation of changes in burden across time.
For each disorder, prevalence data were assembled by conducting systematic reviews of the
published and gray literature to capture data on prevalence, incidence, remission, duration,
and excess mortality [16,18,20,21,27–29]. DisMod-MR, a Bayesian meta-regression tool [11]
developed specifically for GBD 2010, was then used to model prevalence by disorder type, age,
gender, year, region and country. A generalized negative binomial model was estimated for all
Table 1. GBD 2010 Mental, Neurological, and Substance Use Disorders, Estimated Disability Weights, and Prevalent Cases.
Disorders Disability weights Prevalent cases (to the
nearest 100,000)
Neurological disorders
Alzheimer’s disease mild: 0.082 (0.055–0.117); moderate:0.346 (0.233–0.475); severe:0.438 (0.299–0.584) 43,000,000
Parkinson’s disease mild: 0.011 (0.005–0.021); moderate:0.263 (0.179–0.360); severe:0.549 (0.383–0.711) 5,100,000
Epilepsy treated, seizure free:0.072 (0.047–0.106); treated, with recent seizures:0.319
(0.211–0.445); untreated:0.420 (0.279–0.572); severe:0.657 (0.464–0.827)
28,300,000
Multiple sclerosis mild: 0.198 (0.137–0.278); moderate:0.445 (0.303–0.593); severe:0.707 (0.522–0.857) 1,800,000
Migraine 0.433 (0.287–0.593) 1,014,000,000
Tension-type headache 0.04 (0.025–0.062) 1,432,500,000
Substance use disorders
Alcohol dependence mild: 0.25(90.176–0.359); moderate:0.388(0.262–0.529); severe:0.549(0.384–0.708) 94,800,000
Opioid dependence 0.641 (0.459–0.803) 15,500,000
Cocaine dependence 0.376 (0.235–0.553) 6,900,000
Amphetamine dependence 0.353 (0.215–0.525) 17,200,000
Cannabis dependence 0.329 (0.223–0.455) 13,100,000
Mental disorders
Major depressive disorder mild: 0.159 (0.107–0.223); moderate:0.406 (0.276–0.551); severe:0.655 (0.469–0.816) 298,700,000
Dysthymia 0.159 (0.107–0.223) 105,700,000
Bipolar disorder manic: 0.480 (0.323–0.642); depressive: 0.406 (0.276–0.551); residual: 0.035
(0.021–0.055)
58,900,000
Schizophrenia acute: 0.756 (0.571–0.894); residual:0.576 (0.399–0.756) 21,500,000
Anxiety disorders mild: 0.03 (0.017–0.048); moderate:0.149 (0.101–0.210); severe: 0.523 (0.365–0.684) 272,100,000
Eating disorders Anorexia nervosa: 0.223 (0.151–0.313); Bulimia nervosa:0.223 (0.150–0.310) Anorexia: 9,400,000 Bulimia:
8,600,000
Autism 0.259 (0.177–0.362) 14,900,000
Asperger’s syndrome 0.11 (0.073–0.157) 35,500,000
Attention-deﬁcit
hyperactivity disorder
0.049 (0.031–0.074) 36,400,000
Conduct disorder 0.236 (0.031–0.074) 48,700,000
Idiopathic intellectual
disability
mild: 0.031 (0.018–0.049); moderate:0.08 (0.053–0.114); severe:0.126 (0.085–0.176);
profound: 0.157 (0.107–0.221)
30,800,000
Source:[11,12,15,16]; Note: GBD 2010 comorbidity adjustments is applied to disability weights as opposed to prevalent cases so the latter cannot be
summed across disorders that co-occur to avoid any double counting of cases; Prevalent cases were derived from estimates of point prevalence for all
conditions apart from bipolar disorder and headaches where one-year prevalence was used. In addition to the disorders presented here, burden was
estimated for three extra groupings of “other mental disorders”, “other drug use disorders,” and “other neurological disorders.” These were residual
categories made up of rare disorders for which there were insufﬁcient data to estimate prevalence. Instead, we estimated burden for these disorders using
other available data for instance a ratio of YLDs to YLLs for similar or related disorders.
doi:10.1371/journal.pone.0116820.t001
The Global Burden of Mental, Neurological and Substance Use Disorders
PLOS ONE | DOI:10.1371/journal.pone.0116820 February 6, 2015 4 / 14
epidemiological data using super-region, region, and country random effects, as well as two
sets of covariates: study level covariates that adjusted for systematic bias in the raw epidemio-
logical data, and country level covariates that aided the predictive power of the model by ad-
justing for known ecological effects in the data, such as the effect of conflict or economic status
on prevalence.
DisMod-MR also made use of the data available to estimate prevalence for countries and re-
gions for which no raw data were available. Given that the aim of GBD 2010 was to compare
burden caused by diseases and injuries between countries, this approach was considered prefer-
able to the alternative, which was to entirely exclude parts of the world where no local data was
available from GBD estimations, thereby assuming the prevalence of mental, neurological, and
substance use disorders in those countries was zero. The final results provided prevalence esti-
mates for 187 countries, 21 regions, 7 super regions, 20 age groups, men and women, for 1990,
2005, and 2010. Uncertainty around the raw epidemiological data was propagated to the final
DisMod-MR model to provide 95% uncertainty intervals around all prevalence estimates [11].
Disability weights in GBD 2010 quantified the severity of any short- or long-term health
loss. They ranged from zero to one, with zero equivalent to perfect health and one equivalent
to death. Disability weights were estimated for 220 distinct health states that together repre-
sented the non-fatal consequences of diseases and injuries in the study. Population-based
surveys in Bangladesh, Indonesia, Peru, Tanzania, and the United States, in addition to an
open-internet survey (accessible in English, Mandarin, and Spanish), captured the views of
31,038 individuals. In each survey, participants were asked to compare two randomly selected
health states and to identify which of the two they considered healthier. To calculate disability
weights, their responses were anchored on a scale of zero to one, using a series of “population
health equivalence” questions designed to compare overall health benefits of lifesaving or dis-
ease prevention programs[12]. For a number of mental, neurological, and substance use disor-
ders, disability weights were generated for more than one health state to capture differences in
disability within the symptomatic presentation of the disorder (see Table 1 for heath states in-
vestigated for each disorder). For major depressive disorder, for instance, disability weights
were estimated for mild, moderate, and severe states. Survey data on the distribution of these
health states in the population were then used to proportionally aggregate the three disability
weights into an average disability weight for the disorder, which also took into consideration
the proportion of those diagnosed with major depressive disorder who were asymptomatic at
the time of survey [22]. For the headaches, data on the frequency and average duration of epi-
sodes were used to estimate a proportion of time symptomatic.
Finally, microsimulation methods were used to conduct a study-wide comorbidity correc-
tion for all GBD 2010 disability weights. For each age, gender, year, region and country catego-
ry, a hypothetical population of 20,000 individuals was created who would have no, one, two,
or more comorbid conditions, using prevalence data as probabilities. Using a multiplicative
function, a combined disability weight was calculated for all comorbid health states and then
reapportioned to each health state relative to the sum of comorbid disability weights. The aver-
age “corrected” disability for each health state was calculated in each age, gender, year, and
country stratum and the decrement compared to the original disability weight taken as the co-
morbidity correction for YLDs [11].
Estimation of Years of Life Lost to Premature Mortality
YLLs for each disorder were estimated by multiplying deaths occurring as a result of a given
disorder, by the reference standard life expectancy at the age the death occurred. Standard life
expectancy data came from GBD 2010 standard model life tables [12]. The number of deaths
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occurring as a result of each mental, neurological, and substance use disorder was estimated
from cause of death data (by age, gender, year, region and country) available for 235 of 291 dis-
eases and injuries in GBD 2010 [10]. These estimates were based on comprehensive searches of
data sources such as vital registrations, verbal autopsies, and mortality surveillance databases,
dating back to 1980, for 187 countries. Codes from different revisions of the ICD cause of
death directory were matched to GBD 2010’s list of diseases and injuries. Deaths allocated to
unclear or imprecise diagnoses (for example, deaths assigned to conditions that were not likely
to be the underlying cause of death) were reassigned using standard algorithms [13]. Deaths
and YLLs were estimated for schizophrenia, alcohol use disorders, drug use disorders, anorexia
nervosa, epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and the residual
groups of other mental, substance use, and neurological disorders. There were insufficient data
for the remaining mental, neurological, and substance use disorders to enable the allocation of
deaths to specific disorders.
Estimation of Disability-Adjusted Life Years
For each disorder, YLDs and YLLs were summed to estimate DALYs. For disorders with insuf-
ficient data to estimate YLLs, YLDs were equated with DALYs. Uncertainty was estimated at
all stages of the analysis through microsimulation methods and propagated to the final burden
estimates. YLDs, YLLs, and DALYs in this paper are presented at the following levels:
• Global
• Disaggregated by disorder type, age, gender, and year.
• Disaggregated by GBD 2010’s seven super-region groups: East Asia and the Pacific, Eastern
Europe and Central Asia, High-income regions (North America, Australasia, Western Eu-
rope, High-income Asia Pacific, and Southern Latin America), Latin America and the Carib-
bean, North Africa and the Middle East, South Asia, and Sub-Saharan Africa.
• Disaggregated by developed and developing regions.
The terms developed and developing regions are used here rather than high- and low-to-
middle income regions for consistency with the presentation of GBD 2010 estimates. The clas-
sification of countries into regions and regions into super-regions was based on both geograph-
ical proximity and epidemiological likeness in terms of cause of death patterns [1,11].
Materials published by Whiteford and collaborators[15] provide a list of all countries in each
region and super-region. Where age-standardized DALY rates are presented, these were esti-
mated using direct standardization to the global standard population that the WHO proposed
in 2001 (http://www.who.int/healthinfo/paper31.pdf).
Results
Mental, neurological, and substance use disorders accounted for 258 million DALYs in 2010,
which was equivalent to 10.4% of total all-cause DALYs. Within mental, neurological, and sub-
stance use disorders, mental disorders accounted for the highest proportion of DALYs (56.7%),
followed by neurological disorders (28.6%) and substance use disorders (14.7%). For all three
groups of disorders, DALYs occurred across the lifespan (Fig. 1); however, there was a peak in
early adulthood (between ages 20 and 30 years) for mental and substance use disorders com-
pared to neurological disorders, where DALYs were more constant across age groups.
Absolute DALYs for mental, neurological, and substance use disorders increased by 41% be-
tween 1990 and 2010, from 182 million to 258 million DALYs. With the exception of substance
use disorders, this increase was largely due to changes in population growth and aging, with
The Global Burden of Mental, Neurological and Substance Use Disorders
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DALY rates remaining fairly stable over time. Table 2 summarizes age-standardized DALY
rates for 1990 and 2010.
Table 3 summarizes DALYs assigned to each mental, neurological, and substance use disor-
der in 2010. These disorders as a group ranked as the third leading cause of DALYs after car-
diovascular and circulatory diseases (explaining 11.9% of DALYs) and diarrhoea, lower
respiratory infections, meningitis, and other common infectious diseases (explaining 11.4% of
DALYs). The greatest variation in burden within the disorder groupings was for mental disor-
ders. Major depressive disorder was responsible for the highest proportion of mental, neurolog-
ical, and substance use disorder DALYs (24.5%); attention-deficit hyperactivity disorder was
responsible for the lowest (0.2%).
Overall, in 2010, 124 million mental, neurological, and substance use DALYs occurred
among males and 134 million among females. Fig. 2 shows DALY rates for each mental, neuro-
logical, and substance use disorder by gender. Women accounted for more DALYs in most of
the mental and neurological disorders, except for mental disorders occurring in childhood,
schizophrenia, Parkinson’s disease, and epilepsy, where men accounted for more DALYs. Men
also accounted for more DALYs than women in all substance use disorders.
Fig. 3 shows the burden attributable to mental, neurological, and substance use disorders in
2010 by GBD 2010’s super-region groupings, and by developed and developing world regions.
Overall, the burden of these disorders was approximately 1.3 times higher in developed regions
(15.5% of total DALYs) compared to developing regions (9.4% of total DALYs). When disag-
gregated by GBD super-regions, the burden (age standardized rate) of mental, neurological,
and substance use disorders was highest in Eastern Europe and Central Asia and lowest in East
Asia and Pacific. Mental disorders maintained the highest proportion of DALYs in all super-
regions. The greatest variation in DALYs occurred within substance use disorders, where
DALYs were almost three times higher in Eastern Europe and Central Asia, compared to Sub-
Saharan Africa, where DALYs were lowest.
Fig. 4 illustrates the decomposition of global burden by YLDs and YLLs for communicable
diseases, noncommunicable diseases, and injuries. Noncommunicable diseases explained
a large proportion of YLDs and YLLs in 2010, when compared to communicable diseases and
injuries. Within this group, mental, neurological, and substance use disorders were responsible
Fig 1. Absolute DALYs Attributable to Mental, Neurological, and Substance Use Disorders, by Age, 2010.
doi:10.1371/journal.pone.0116820.g001
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for 28.5% of all YLDs, making them the leading cause of YLDs worldwide. In comparison, they
contributed to only 2.3% of YLLs. Deaths and YLLs could be assigned to a mental, neurological,
and substance use disorder only when the disorder was considered as a direct cause of death in
the ICD cause of death directory. Using this approach, the majority of excess deaths in individ-
uals with a mental disorder, in particular, were coded to the direct physical cause of death (for
example, suicide deaths were coded under injuries as self-harm) rather than to the disorder.
Discussion
Mental, neurological, and substance use disorders are a leading cause of the disease burden
worldwide, substantially contributing to health loss across the lifespan. DALY rates are lower
in developing compared to developed regions. However, population growth and a changing
age profile are producing a shift in the disease burden from communicable to noncommunic-
able diseases and from YLLs to YLDs. This demographic and epidemiological transition is
Table 2. Age-Standardized DALY Rates Attributable to Mental, Neurological, and Substance Use Disorders, 1990 and 2010.
Age standardized DALY rates (per 100,000)
Male Female
Disorder 1990 2010 1990 2010
Neurological disorders
Alzheimer’s disease and other dementias 125.7 155.5 153.7 178.6
Parkinson’s disease 32.7 36.6 23.2 23.3
Epilepsy 261.6 269.3 226.0 232.9
Multiple sclerosis 16.3 12.3 23.7 19.8
Migraine 233.1 236.6 405.9 415.8
Tension-type headache 24.1 24.0 28.3 28.3
Other neurological disorders 228.0 259.9 200.0 266.7
Substance use disorders
Alcohol use disorders 431.0 409.9 117.2 106.0
Opioid use disorders 139.0 184.4 63.8 78.4
Cocaine use disorders 22.5 22.0 10.3 9.7
Amphetamine use disorders 45.4 47.3 26.9 27.6
Cannabis use disorders 38.8 36.7 22.3 21.3
Other drug use disorders 83.7 97.0 44.6 47.9
Mental disorders
Major depressive disorder 694.8 689.9 1171.7 1161.2
Dysthymia 135.3 135.8 189.7 190.0
Bipolar affective disorder 172.0 172.1 204.6 204.8
Schizophrenia 230.7 223.0 187.8 180.6
Anxiety disorders 274.3 273.0 508.9 510.3
Eating disorders 4.4 3.9 47.6 59.5
Autism 85.1 85.8 29.5 29.6
Asperger’s syndrome 85.2 85.0 20.3 20.3
Attention-deﬁcit hyperactivity disorder 10.8 10.6 3.1 3.1
Conduct disorder 111.9 113.3 47.0 47.6
Idiopathic intellectual disability 25.3 17.7 18.2 11.9
Other mental and behavioral disorders 25.5 23.3 21.5 20.8
doi:10.1371/journal.pone.0116820.t002
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contributing to a rise in the burden of mental, neurological, and substance use disorders, par-
ticularly in developing regions.
Geographic variations exist within DALY rates. Mental disorder DALYs are highest in
North Africa and the Middle East, substance use disorder DALYs are highest in Eastern Europe
and Central Asia, and neurological disorders DALYs are highest in Asia South. These regional
differences were driven by the global distribution of disorder prevalence and, in some in-
stances, deaths. Analysis of GBD 2010 prevalence data for mental disorders, for example,
highlighted the effect of conflict status on estimates. The prevalence of major depressive disor-
der and anxiety disorders was highest in countries with a history of conflict or war, many of
which are in North Africa and Middle East [17,22]. The prevalence of opioid and cannabis de-
pendence was highest in Australasia and Western Europe [19,20]. Cocaine dependence was
highest in North America, High-income, and Southern Latin America. Although there was less
Table 3. DALYs (absolute numbers, and proportions) attributable to mental, neurological and substance use disorders in 2010.
Disorder Absolute DALYs (to nearest
100,000)
Proportion of total (all cause)
DALYs (%)
Proportion of mental, neurological, and
substance use DALYs (%)
Neurological disorders
Alzheimer’s disease and other
dementias
11,400,000 0.5 4.4
Parkinson’s disease 1,900,000 0.1 0.7
Epilepsy 17,400,000 0.7 6.8
Multiple sclerosis 1,100,000 0.04 0.4
Migraine 22,400,000 0.9 8.7
Tension-type headache 1,800,000 0.1 0.7
Other neurological disorders 17,900,000 0.7 6.9
Substance use disorders
Alcohol dependence 17,700,000 0.7 6.9
Opioid dependence 9,200,000 0.4 3.6
Cocaine dependence 1,100,000 0.04 0.4
Amphetamine dependence 2,600,000 0.1 1.0
Cannabis dependence 2,100,000 0.1 0.8
Other drug use disorders 5,100,000 0.2 2.0
Mental disorders
Major depressive disorder 63,200,000 2.5 24.5
Dysthymia 11,100,000 0.4 4.3
Bipolar disorder 12,900,000 0.5 5.0
Schizophrenia 13,600,000 0.5 5.3
Anxiety disorders 26,800,000 1.1 10.4
Eating disorders 2,200,000 0.1 0.9
Autism 4,000,000 0.2 1.6
Asperger’s syndrome 3,700,000 0.1 1.4
Attention-deﬁcit hyperactivity
disorder
500,000 0.02 0.2
Conduct disorder 5,800,000 0.2 2.2
Idiopathic intellectual disability 1,000,000 0.04 0.4
Other mental disorders 1,500,000 0.1 0.6
Note: DALYs presented have been aggregated across all countries, gender, and age groups for 2010.
doi:10.1371/journal.pone.0116820.t003
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regional variation in the prevalence of amphetamine dependence, the rates were highest in
South East Asia and Australasia [17].
The largest contributor of YLLs for substance use disorder was opioid dependence, with
particularly high proportions of deaths due to opioid dependence occurring in the North
Fig 2. Age-Standardized DALY Rates Attributable to Individual Mental, Neurological, and Substance Use Disorders, by Gender, 2010.
doi:10.1371/journal.pone.0116820.g002
Fig 3. Age-Standardized DALY Rates Attributable to Mental, Neurological, and Substance Use Disorders, by Region, 2010.
doi:10.1371/journal.pone.0116820.g003
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America, High-income, Europe Eastern, and Sub-Saharan Africa Southern. In many Eastern
European and Sub-Saharan African countries, access to interventions found to be effective in
reducing the risk of mortality from opioid dependence—such as opioid substitution therapy,
needle and syringe programs, and HIV treatment for those who are HIV-positive—is limited.
Access to these interventions in North America, High-income varies subnationally, with insuf-
ficient data to determine the access rates at the national level [19]. Prevalence and deaths attrib-
utable to Alzheimer’s disease were highest in North America, High-income, Europe Western,
and Australasia. In contrast, prevalence and deaths attributable to epilepsy was highest in Sub-
Saharan Africa.
Mental, neurological and substance use disorders rarely occur in isolation and can increase
one’s risk of other diseases and injuries. This has significant consequences on life expectancy
[30,31]. Previous studies have shown that up to 80% of deaths in those with mental, neurologi-
cal and substance use disorders occur as a result of a comorbid physical illness such as cardio-
vascular disease or cancer [30,31]. For disorders like epilepsy, rates of excess-mortality also
vary by world regions with higher rates reported in some developing countries [32]. In spite of
this, YLDs explained a larger proportion of the burden due to mental, neurological and sub-
stance use disorders compared to YLLs in GBD 2010. To estimate YLLs, GBD 2010 followed
the ICD-10 cause of death categories, whereby deaths can only be assigned to a given condition
when the disorder is considered a direct cause of death. This approach can only account for
some of the excess deaths attributable to mental, neurological, and substance use disorders,
given that deaths will also be coded to the direct physical cause of death. For instance, ischemic
heart disease or suicide deaths occurring as a result of mental, neurological and substance use
disorders will be coded to cardiovascular disease and injuries rather than to the mental, neuro-
logical or substance use disorder.
Fig 4. Proportion of Global YLDs and YLLs Attributable to Mental, Neurological, and Substance Use Disorders, 2010.
doi:10.1371/journal.pone.0116820.g004
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The additional burden attributable to mental, neurological, and substance use disorders as
a risk factor for other health outcomes can be investigated through comparative risk assessment
analysis, which compares the current health status to a theoretical-minimum-risk exposure, in this
case, the counterfactual status of the absence of mental, neurological, and substance use disorders
in the population. The use of this method to estimate the additional burden due to mental and sub-
stance use disorders as risk factors for suicide showed that these disorders could account for over
50% of suicide YLLs in GBD 2010. These additional suicide YLLs would have increased the overall
burden of mental and substance use disorders in 2010 from 7.4% to 8.3% of global DALYs [33].
Although not adopted in GBD 2010, the use of age weighting in many economic analyses and
in earlier GBD studies[34] recognizes and attempts to incorporate the social preference for
avoiding health loss in young adults. In spite of its absence in GBD 2010 estimates, the peak im-
pact of mental, neurological, and substance use disorders in early adulthood remained and dem-
onstrated the ubiquitous effect of these disorders at a time of life when individuals are starting to
make significant social and economic contributions to their families and societies. Although the
peak burden of mental, neurological, and substance use disorders is found in young adults, there
is, unlike many chronic diseases, a significant burden in children and younger adolescents. For
countries such as those in Sub-Saharan Africa where children constitute 40% of the population
[35], these findings highlight the need for prevention and treatment services targeted to children
and adolescents. The availability of such services is often more sporadic than for adult services.
Within the mental, neurological, and substance use disorder group, particular disorders make
a disproportionate contribution to the burden; for these, the need for cost-effective interventions
is highest. Depressive and anxiety disorders are very prevalent and are significant contributors to
the burden. Treatment rates for these disorders are low in most countries, as they are for epilep-
sy, migraine, alcohol, and opioid dependence, the other large contributors to disease burden.
Where cost-effective prevention or treatment of mental, neurological, and substance use disor-
ders is less attainable, services can still provide treatment and support that mitigate their impacts.
Pharmacological and psychosocial interventions may assist individuals with schizophrenia to live
a better quality of life. Treatment and support services may alleviate the impact of dementia, a dis-
order that has to be addressed most urgently in countries with rapidly aging populations.
Although it represents the most comprehensive assessment of the burden due to mental,
neurological, and substance use disorders to date, not all elements of the burden were captured.
By focusing on health loss, burden in GBD 2010 does not extend to welfare loss; hence, it does
not capture all of the consequences of mental, neurological, and substance use disorders for
families or societies. Disability weights in GBD 2010 were derived from surveying the general
population (rather than by clinicians, as in previous GBD studies), with the aim of better cap-
turing the societal view of health loss. Nevertheless, adequately encompassing the complexity
of health states that represent mental, neurological, and substance use disorders within the sur-
vey was challenging; the extent to which the GBD 2010 disability weights entirely reflected the
associated health loss is an important area for further research. Finally, the established defini-
tions of mental, neurological, and substance use disorders used in the study may not be
sensitive to non-Western presentation of these disorders, which may have led to an underesti-
mation of burden in developing regions. A task for upcoming GBD analyses will be to explore
the extent to which certain disorders are misdiagnosed as other mental or physical disorders in
developing countries and the consequence on burden.
Conclusions
Mental, neurological, and substance use disorders contribute to a significant proportion of the
global burden of disease and will continue to do so as the shift in burden from communicable
The Global Burden of Mental, Neurological and Substance Use Disorders
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to noncommunicable diseases continues. Health systems worldwide need to respond to this ris-
ing burden by implementing proven, cost-effective interventions; where these are limited, it
will be important to support the research necessary to develop better prevention and
treatment options.
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